Cancer stem cells
Support assay development and evaluation for the collection and analysis of CSC pathways inhibition in clinical trials.
Lead principal investigator: Michael Reedijk, University Health Network.
Co-applicants: Laurie Ailles, Amit Oza, Lillian Siu, Ming-Sound Tsao (University Health Network).
Objective: To establish cancer stem cell (CSC) based end points in evaluating therapies that target the Notch pathway.
- Assess if clinical outcomes to Notch inhibition will correlate with measurable parameters including CSC frequency and Notch biomarker profile;
- Establish breast and other solid tumor xenograft models to be used to study Notch therapeutics and CSC;
- Develop and establish SOPs.